肺CXCR4分子影像预测吡非尼酮治疗IPF结局
该研究探讨肺CXCR4表达分子影像能否预测IPF患者对吡非尼酮的应答与预后。对28例IPF患者行68Ga-pentixafor PET-CT,16例在治疗6-12周后复查。基线CXCR4信号与GAP分期及HRCT评分相关,治疗后早期信号变化与12个月FVC病程相关,随访PET高信号者12个月结局更差。
要点
- 68Ga-pentixafor PET可无创显示IPF肺纤维化区域CXCR4表达上调。
- 启动吡非尼酮后6-12周CXCR4信号变化与12个月FVC病程相关。
- 治疗6周后随访PET高CXCR4信号提示12个月结局更差。
核心结论
- CXCR4靶向PET成像可反映IPF疾病活动并预测吡非尼酮治疗患者的结局。
- 肺CXCR4信号有望成为个体化指导抗纤维化治疗的生物标志物。
研究设计与样本
- 对28例IPF患者行68Ga-pentixafor PET-CT并与基线临床特征比较。
- 其中16例在启动吡非尼酮治疗6至12周后获得随访扫描。
- 患者门诊随访至少12个月。
- 另通过肺组织免疫组化及BAL逆转录聚合酶链反应分析CXCR4表达。
主要发现
- 免疫组化显示广泛纤维化重塑区域上皮细胞和巨噬细胞CXCR4高染色。
- 靶向PET显示肺纤维化区域CXCR4上调,尤其胸膜下蜂窝区。
- 基线CXCR4信号与GAP分期相关(r=0.44;P=.02),与HRCT评分相关(r=0.38;P=.04)。
- 启动吡非尼酮后早期CXCR4信号变化与12个月FVC长期病程相关(r=-0.75;P=.0008)。
- 治疗6周后随访PET肺CXCR4高信号者12个月结局显著更差(P=.002)。
临床怎么用
- 对IPF患者可考虑用68Ga-pentixafor PET评估肺CXCR4表达以辅助判断疾病活动。
- 吡非尼酮治疗后早期复查CXCR4 PET或有助于预判12个月FVC病程与结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which two antifibrotic drugs recently were approved. However, an unmet need exists to predict responses to antifibrotic treatment, such as pirfenidone. Recent data suggest that upregulated expression of CXCR4 is indicative of outcomes in IPF. RESEARCH QUESTION: Can quantitative, molecular imaging of pulmonary CXCR4 expression as a biomarker for disease activity predict response to the targeted treatment pirfenidone and prognosis in patients with IPF? STUDY DESIGN AND METHODS: CXCR4 expression was analyzed by immunohistochemistry examination of lung tissues and reverse-transcriptase polymerase chain reaction analysis of BAL. PET-CT scanning with the specific CXCR4 ligand 68Ga-pentixafor was performed in 28 IPF patients and compared with baseline clinical characteristics. In 16 patients, a follow-up scan was obtained 6 to 12 weeks after initiation of treatment with pirfenidone. Patients were followed up in our outpatient clinic for ≥ 12 months. RESULTS: Immunohistochemistry analysis showed high CXCR4 staining of epithelial cells and macrophages in areas with vast fibrotic remodeling. Targeted PET scanning revealed CXCR4 upregulation in fibrotic areas of the lungs, particularly in zones with subpleural honeycombing. Baseline CXCR4 signal demonstrated a significant correlation with Gender Age Physiology stage (r = 0.44; P = .02) and with high-resolution CT scan score (r = 0.38; P = .04). Early changes in CXCR4 signal after initiation of pirfenidone treatment correlated with the long-term course of FVC after 12 months (r = -0.75; P = .0008). Moreover, patients with a high pulmonary CXCR4 signal on follow-up PET scan after 6 weeks into treatment demonstrated a statistically significant worse outcome at 12 months (P = .002). In multiple regression analysis, pulmonary CXCR4 signal on follow-up PET scan emerged as the only independent predictor of long-term outcome (P = .0226). INTERPRETATION: CXCR4-targeted PET imaging identified disease activity and predicted outcome of IPF patients treated with pirfenidone. It may serve as a future biomarker for personalized guidance of antifibrotic treatment.
引用
- Derlin T, Jaeger B, Jonigk D, et al. Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest. 2020. PMID: 32822674. doi:10.1016/j.chest.2020.08.2043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。